KOSDAQElectrical Equipment494120

Curiosis

₩11,270▼ 4.97%2026-11-18 close
Market Cap
₩172B
Turnover
₩3B
Volume
260K
Shares out.
15.3M
PER
—
PBR
—
EPS
-₩599
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

ODM expansion meets persistent losses

Curiosis is widening its global ODM supply contracts, but disclosed results show losses through the third quarter of 2026, so how fast those contracts convert into revenue is the next checkpoint.

  1. 1

    Revenue reached KRW 7.3 billion in 2025, up 34.9% year on year, while the operating loss widened to KRW 7.53 billion.

  2. 2

    Third-quarter 2026 revenue was KRW 1.32 billion, up 15.1% from a year earlier, but the operating loss widened to KRW 2.75 billion.

  3. 3

    Curiosis renewed its China supply contract with Revvity in May 2026 at about KRW 11 billion and signed a five-year global supply deal with Merck's EMD Millipore in July 2026.

  4. 4

    The 2026 consensus compiled by FnGuide as of July 2026 is KRW 15.9 billion in revenue and a KRW 1.2 billion operating loss, which implies roughly KRW 10 billion of fourth-quarter revenue on top of the first three quarters.

  5. 5

    The debt ratio fell to 21.4% at the end of 2025 from 78.9% in 2024, while operating cash flow worsened to -KRW 7.35 billion.

02

Business structure

Curiosis is a lab automation specialist founded in 2015. Its core product is the Celloger live-cell imaging system, which automatically observes and analyzes cells, and its own-brand lineup also includes the CPX automated colony picker, Cellpuri and MSP.

The company says it holds six core proprietary technologies, including opto-mechatronics, electronics and control, mechanical design, software, cell separation and mass production, and that it internalizes key components to lower manufacturing costs.

The business has two pillars: direct sales of its own-brand instruments and original design manufacturing (ODM) supply to global companies. At its 2025 listing, the company described Celloger direct sales and global ODM revenue as the two pillars.

Its main ODM customer is the US life science instrument maker Revvity; the China supply contract for CPX was renewed in May 2026 at about KRW 11 billion and extended to March 2029.

In July 2026 the company signed a five-year global supply contract with EMD Millipore, a unit of Germany's Merck, for live-cell imaging instruments used to observe organoids. That product carries a lower unit price than the higher-spec Revvity model, but Merck's global sales network could expand volume.

Exports accounted for 69.8% of revenue in the first half of 2025, and the company says its live-cell imaging systems are exported to 28 countries.

Applications span drug discovery, cell therapy manufacturing and synthetic biology, and the company points to the scarcity of dedicated lab automation specialists in Korea as a differentiator.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩2.1B−180.7%
2025Q4₩2.7B-₩2.3B−85.4%
2026Q1₩1.1B-₩1.6B−140.2%
2026Q2₩3.5B-₩1.9B−53.8%
2026Q3₩1.3B-₩2.8B−207.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩5.4B-₩6.2B-₩4.9B−114.6%−50.3%78.9%
2025₩7.3B-₩7.5B-₩7.8B−103.1%−27.5%21.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Revenue reached KRW 7.3 billion in 2025, up 34.9% from KRW 5.41 billion in 2024. Over the same period the operating loss widened from KRW 6.21 billion to KRW 7.53 billion, and the company has posted losses for two consecutive years from 2024 through 2025.

The operating margin, which measures the operating loss against revenue, improved from -114.6% to -103.1%, because revenue grew faster than the loss, although the absolute loss became larger.

The net loss attributable to controlling shareholders widened from KRW 4.88 billion to KRW 7.76 billion, and the net loss including non-controlling interests widened from KRW 4.82 billion to KRW 7.86 billion.

Total equity at the end of 2025 was KRW 28.2 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 6.03 billion. The debt ratio fell from 78.9% to 21.4%, with the growth in equity likely linked to the November 2025 IPO.

Operating cash flow worsened from -KRW 4.78 billion in 2024 to -KRW 7.35 billion in 2025.

Quarterly revenue ran at KRW 1.15 billion in the third quarter of 2025, KRW 2.68 billion in the fourth quarter (up 133.0% quarter on quarter), KRW 1.15 billion in the first quarter of 2026 (down 57.3%), KRW 3.47 billion in the second quarter (up 203.1%) and KRW 1.32 billion in the third quarter (down 61.9%), so the swings were large.

Quarterly operating losses were KRW 2.08 billion, KRW 2.29 billion, KRW 1.61 billion, KRW 1.87 billion and KRW 2.75 billion over the five quarters from the third quarter of 2025 through the third quarter of 2026, which the disclosures classify as five consecutive loss-making quarters.

In the third quarter of 2026 revenue rose 15.1% from a year earlier while the operating loss widened, and higher fixed costs from capacity expansion and hiring may be part of the reason.

The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totaled KRW 8.27 billion.

05

Industry analysis

Demand for lab automation surged after the pandemic, as mass production of mRNA vaccines and a shortage of skilled technicians exposed the limits of manual work.

The company says demand is spreading beyond drug discovery and cell therapy manufacturing into automation of in-hospital diagnostics and organoid-based drug discovery platforms.

Global instrument makers are moving in the same direction: Merck acquired the organoid specialist HUB Organoids in 2025, and Curiosis's organoid observation instrument supply fits that strategy. Securities analysts describe the company's earnings as still in an early growth stage.

In competition, Korea has few dedicated lab automation specialists, which gives the company a differentiated position domestically. Overseas, large instrument makers are present, but Curiosis's relationship with them is more clearly one of ODM supply partnership than head-to-head competition.

The company says CPX can handle smaller colonies than competing products, a claim that reflects its own description of the product.

CPX received an NEP certification from the Korea Agency for Technology and Standards under the Ministry of Trade, Industry and Energy in May 2026, and the company says it has secured one NET certification and three NEP certifications so far.

In Korea, the instrument has been introduced at key K-Biofoundry institutions, including the Korea Research Institute of Bioscience and Biotechnology, where it runs core processes.

06

Outlook

The 2026 consensus compiled by FnGuide as of July 2026 is KRW 15.9 billion in revenue and a KRW 1.2 billion operating loss, implying revenue more than double the 2025 level and a sharply smaller operating loss.

Adding the first three quarters of disclosed 2026 revenue, reaching the consensus requires roughly KRW 10 billion of fourth-quarter revenue, and because fourth-quarter revenue jumped sharply in 2025, the size of fourth-quarter orders is the key variable.

Securities analysts expected Merck's first purchase order in the third quarter of 2026, a soft launch in the fourth quarter, and full revenue contribution from 2027. A purchase order above 10% of prior-year revenue would trigger a separate supply contract disclosure.

The company is developing new ODM models for Revvity and seeking to extend contract regions beyond China into Europe and other markets. Candidates for follow-on ODM products include an automated colony picker, Celloger Pro and the large multilayer cell culture instrument Celloger Stack-H.

Celloger Stack-H was shown at AACR in the United States in April 2026, and its core technology patent was registered in May 2026. On the production side, the third phase of the Yongin plant expansion is targeted for completion in the second quarter of 2027.

At its 2025 listing the company set targets of KRW 47.2 billion in revenue and a 38% operating margin for 2028, and it had pointed to a return to operating profit in 2026. With the 2026 consensus still showing an operating loss, progress against these targets is the next point to track.

07

Valuation

PER
—
PBR
—
ROE
-62.0%
EPS
-₩599
BPS
—
Dividend per share
₩0

Because the last four quarters show net losses, a P/E ratio cannot be calculated, and the company pays no dividend, so dividend-based comparison does not apply. Market capitalization sits well above book equity, a premium to net assets that is large in relative terms.

At the 2025 listing, valuation was set by applying an average peer P/E to estimated 2027 and 2028 net income, with a discount rate applied.

Because the company was loss-making, it used forecast earnings rather than past results, so interpreting the valuation depends on whether those forecast earnings translate into actual profit.

In June 2026 the stock was designated for one day as an investment caution issue after heavy selling concentrated in a few accounts and a sharp price decline over three days.

In August 2026 a 1-for-1 bonus issue raised the listed share count to 15,259,764, which changes the basis for comparing per-share metrics over time.

After the stock rose to about four times the offering price on its first day and then fell sharply, the post-listing price range is difficult to compare directly with early trading levels.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Wider global ODM pipeline

The Revvity supply contract was renewed in May 2026 at about KRW 11 billion and extended to March 2029. In July 2026 the company signed a five-year global supply deal with a Merck unit, and it expects Merck's sales network to expand volume. Securities analysts expect meaningful Merck revenue from 2027.

Revenue growth and a narrowing loss ratio

In 2025, higher sales came with a smaller operating loss relative to revenue. Third-quarter 2026 revenue also grew 15.1% from a year earlier. The 2026 consensus points to revenue more than doubling and a much smaller operating loss.

Balance sheet and technology assets

The debt ratio fell to 21.4% at the end of 2025 from 78.9% in 2024, and total liabilities stood at KRW 6.03 billion. The company points to six core technologies and in-house component production as strengths, and a core patent for Celloger Stack-H was registered in May 2026. It has said IPO proceeds will fund plant expansion and talent acquisition.

09

Bear factors

Persistent operating losses

The 2025 operating loss widened to KRW 7.53 billion, and operating cash flow deteriorated to -KRW 7.35 billion. The disclosures record five consecutive loss-making quarters from the third quarter of 2025 through the third quarter of 2026.

In the third quarter of 2026 the operating loss widened to KRW 2.75 billion from a year earlier even as revenue grew.

Large swings in quarterly revenue

Quarterly revenue moved from KRW 2.68 billion in the fourth quarter of 2025 to KRW 1.15 billion in the first quarter of 2026, then KRW 3.47 billion and KRW 1.32 billion. Reaching the consensus requires roughly KRW 10 billion more in the fourth quarter. If the fourth-quarter concentration does not materialize, the annual outlook could diverge sharply.

Share price volatility and supply overhang

After a sharp first-day rise the shares fell significantly, and in June 2026 the stock was designated for one day as an investment caution issue. The August 2026 bonus issue increased the listed share count, and lock-up shares are scheduled to be released in stages. As a loss-making company, the share price may respond more to supply factors than to earnings releases.

10

Risk factors

Customer concentration and ODM dependence

Much of the revenue growth depends on ODM orders from global partners such as Revvity and Merck. Whether initial purchase orders become recurring revenue is the key variable. Changes in a partner's sales strategy or volume plans would flow directly into the company's revenue.

Capacity expansion and certification timing

The third phase of expansion is targeted for the second quarter of 2027, and the company has said GMP certification takes more than a year. The launch of the CPX-S model and follow-on ODM products also need to stay on schedule. If expansion and certification slip, fixed-cost pressure could weigh on results for longer.

Trading concentration and float changes

In June 2026 a concentrated sell-side trade among a small number of accounts led to an investment caution designation. The bonus issue increased tradable shares and liquidity, but analysts have noted it could also raise short-term volatility. Employee stock ownership lock-up releases and further lock-up expirations remain supply variables.

11

What to watch next

  1. November 25, 2026

    The date the employee stock ownership lock-up on 41,190 shares ends. The supply impact of the released shares on trading volume is the point to watch.

  2. End of December 2026

    Whether Merck's soft launch takes place in the fourth quarter and whether the first purchase order is received. An order above 10% of prior-year revenue would trigger a separate supply contract disclosure.

  3. Late March 2027

    The 2026 annual report will confirm fourth-quarter and full-year results in DART filings. The point to check is fourth-quarter revenue against the consensus and the size of the annual operating loss.

  4. Q2 2027

    The target completion of the third phase of the Yongin plant expansion. The point to check is whether capacity expansion stays on schedule and matches follow-on ODM volumes.

  5. November 12, 2028

    The end of the lock-up on 2,123,145 shares listed through the bonus issue. It is a supply variable as this large block becomes tradable.

12

Overall view

Curiosis designs and manufactures lab automation instruments in-house and is widening its revenue base through ODM supply contracts with Revvity, Merck and others. Revenue rose 34.9% in 2025, and the operating margin improved from -114.6% to -103.1%.

However, the operating loss widened to KRW 7.53 billion, and the disclosures record five consecutive loss-making quarters from the third quarter of 2025 through the third quarter of 2026.

The 2026 consensus expects a smaller loss, but adding the first three quarters of disclosed revenue, reaching it requires roughly KRW 10 billion more in the fourth quarter. The debt ratio improved to 21.4% at the end of 2025, while operating cash flow worsened to -KRW 7.35 billion.

Because the company is loss-making, its valuation cannot be explained by a P/E ratio, so whether forecast earnings translate into actual profit is central. The next checkpoints are Merck's first purchase order, the 2026 annual report and completion of the Yongin expansion in the second quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. mt.co.kr
  3. newstopkorea.com
  4. mt.co.kr
  5. newswell.co.kr
  6. m.newsprime.co.kr
  7. biz.heraldcorp.com
  8. newstopkorea.com
  9. news.nate.com
  10. news.nate.com
  11. newspim.com
  12. m.news.nate.com
  13. topstarnews.net
  14. topstarnews.net
  15. curiosis.co.kr
  16. m.news.nate.com
  17. cbci.co.kr
  18. curiosis.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis